Based on the recognition of IDH mutations as key disease-defining features of astrocytomas and oligodendrogliomas that reliably distinguish them from glioblastomas, assessment of the IDH status has become an integral part of the diagnostic algorithm for glioma classification. This evidence concerns the gene IDH1 and central nervous system cancer.